WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Bayer jointly announced an acquisition agreement …